KIRYAT ONO, ISRAEL and EDISON, N.J., July 22, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc., a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic ...
Pooled data analysis of efficacy and safety from Phase 2b and Phase 3 data sets in patients with early-stage Parkinson’s disease (PD) support P2B001 as a first line, once-daily treatment choice for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback